Please assess the completion status of the following clinical trial:

Trial Title: Brief Behavioral Therapy in Improving Sleep Disorders in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed breast cancer (stage I, II, III)~* Be receiving chemotherapy in either weekly, 2-week or 3-week cycles and have at least 6 weeks of chemotherapy treatment remaining; patients are eligible any time before chemotherapy cycle 3 if on a 2- or 3-week cycle, or cycle 4 if on a 1-week cycle; (Note: use of biologics \[e.g., Herceptin (trastuzumab)\] is permitted)~  * For patients on a weekly regimen, there should be at least 3 dosages of chemotherapy remaining~ * For patients on either a 2 week or 3 week cycle, there should be at least 2 dosages of chemotherapy remaining~ * Patients will not be dropped from the study if their chemotherapy is discontinued after they are enrolled~* Report sleep disturbance of 8 (sum total of all 7 items) or greater on the Insomnia Severity Index~  * (Note: this measure will be repeated again at baseline assessment)~* Report sleep problems that began or got worse with the diagnosis of cancer or with chemotherapy; (did your sleep problems begin or get worse with the diagnosis of cancer or with chemotherapy?)~* Be able to speak and read English~* Patients can take sleep aids (e.g., hypnotics and sedatives) for insomnia if they use sleep aids as needed; patients taking sleep aids every night are excluded; use of melatonin every night is permitted and these patients are not excluded~* Be able and willing to wear an Actiwatch for the entire 24 hours of each day they are scheduled to wear it~Exclusion Criteria:~* Have diagnosis of breast cancer stage IV~* Have sleep problems that began before diagnosis and have not changed since diagnosis~* Self-report or have a medical record of an unstable comorbid medical or psychiatric condition that would make it unsafe or impossible to adhere to the study protocol~* Have a clinical diagnosis of sleep apnea or restless leg syndrome~* Be unable or unwilling to discontinue anxiolytic medication within 4 hours of intervention sessions~* Take medication for sleep (e.g., hypnotics and sedatives) every night; melatonin is permitted~* Patients who are shift workers are excluded; shift worker is defined as someone who has irregular work and sleep hours (such as working a non-traditional schedule: e.g., 4pm-midnight or 10pm-6am; a rotating schedule e.g., alternating between day and night shifts, or starting work between 4am and 7am)~* Have an implanted device for heart failure (e.g., pacemaker, defibrillator, left ventricular assist device, etc.)

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (BBT intervention) (Type: EXPERIMENTAL): Patients undergo BBT intervention, comprising insomnia education, stimulus control, discouragement of napping and encouragement of exercise, and sleep compression over two 60 minute face-to-face sessions in weeks 1 and 3 or 4, and four 15 minute telephone sessions in weeks 2, 3, 5, and 6 or 2, 4, 5, and 6.
- Arm II (control) (Type: ACTIVE_COMPARATOR): Patients undergo HEAL comprising nutritional education and suggestions for symptom management over two 60 minute face-to-face sessions in weeks 1 and 3 or 4, and four 15 minute telephone sessions in weeks 2, 3, 5, and 6 or 2, 4, 5, and 6.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete